Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. (ITCI) Stock Overview
Explore Intra-Cellular Therapies, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
14B
P/E Ratio
-182.12
EPS (TTM)
$-0.73
ROE
-0.07%
ITCI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Intra-Cellular Therapies, Inc. (ITCI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $129.26.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -182.12 and a market capitalization of 14B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.